Andrew J. Schwab's Net Worth

$2.49 Billion

Estimate Recalculated Feb 20, 2024 07:43PM EST

Who is Andrew J. Schwab?

Andrew J. Schwab has an estimated net worth of $2.49 Billion. This is based on reported shares across multiple companies, which include Enliven Therapeutics, Inc., Skye Bioscience, Inc., CinCor Pharma, Inc., Flexion Therapeutics Inc, Crinetics Pharmaceuticals, Inc., Entrada Therapeutics, Inc., Vor Biopharma Inc., Pear Therapeutics, Inc., IDEAYA Biosciences, Inc., Rallybio Corp, ARVINAS, INC., 5:01 Acquisition Corp., IMPEL NEUROPHARMA INC, Cidara Therapeutics, Inc., VIVEVE MEDICAL, INC., scPharmaceuticals Inc., Cabaletta Bio, Inc., Akouos, Inc., Homology Medicines, Inc., Aprea Therapeutics, Inc., Audentes Therapeutics, Inc., PHASERX, INC., and EPIRUS Biopharmaceuticals, Inc..

SEC CIK

Andrew J. Schwab's CIK is 0001598549

Past Insider Trading and Trends

2019 was Andrew J. Schwab's most active year for acquiring shares with 28 total transactions. Andrew J. Schwab's most active month to acquire stocks was the month of January. 2022 was Andrew J. Schwab's most active year for disposing of shares, totalling 56 transactions. Andrew J. Schwab's most active month to dispose stocks was the month of October. 2022 saw Andrew J. Schwab paying a total of $25,520,000.00 for 4,937,646 shares, this is the most they've acquired in one year. In 2019 Andrew J. Schwab cashed out on 13,292,745 shares for a total of $54,804,484.83, their largest year based on trade value.

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

Enliven Therapeutics, Inc. (ELVN) Snapshot price: $15.38

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-17.70%
-825.00K
$14.90
-$12,292,500.00
3.84M
Feb 14
Form 4
-9.69%
-500.00K
$15.00
-$7,500,000.00
4.66M
Jan 31
Form 4
-3.69%
-197.50K
$15.00
-$2,962,500.00
5.16M
Sep 26
Form 4
-7.59%
-440.00K
$16.00
-$7,040,000.00
5.36M
Aug 24
Form 4
0
0
Feb 23
Form 4
5.8M
5.8M
Feb 23
Form 3
0
0
No matching records found

Skye Bioscience, Inc. (SKYE) Snapshot price: $4.98

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
+190.18%
5.21M
$2.31
$12,026,030.94
7.94M
Jan 31
Form 4
0
0
Nov 6
Form 4
0
0
Aug 25
Form 4
1.13B
$0.01
$7,048,922.90
1.13B
Aug 18
Form 3
0
0
No matching records found

No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-100.00%
-4.94M
0
Feb 24
Form 4
+15.62%
600K
$30.00
$18,000,000.00
4.44M
Aug 15
Form 4
4.34M
$16.00
4.34M
Jan 11
Form 3
0
0
No matching records found

Flexion Therapeutics Inc No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
0
0
Mar 3
Form 4
+12,194.30%
1.5M
1.51M
Feb 18
Form 3
0
0
No matching records found

Crinetics Pharmaceuticals, Inc. (CRNX) Snapshot price: $37.76

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-9.57%
-250.00K
$22.20
-$5,550,000.00
2.36M
Jun 21
Form 4
-5.60%
-154.84K
$24.25
-$3,754,954.14
2.61M
Mar 18
Form 4
-14.35%
-464.83K
2.77M
Feb 20
Form 4
-7.49%
-262.15K
$21.88
-$5,734,596.87
3.24M
Jan 22
Form 4
+103.40%
3.5M
$17.00
$1,955,000.00
6.88M
Jul 20
Form 3
0
0
No matching records found